Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis
- PMID: 28461145
- DOI: 10.1016/j.ijsu.2017.04.057
Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis
Abstract
Background: Several prospective controlled trials have assessed the safety and efficacy of drug-coated balloon angioplasty (DCBA) versus standard balloon angioplasty (POBA) for femoropopliteal in-stent restenosis (ISR). We therefore performed a meta-analysis of prospective controlled trials to pool the results of these trials and obtain more reliable conclusions.
Methods and results: Prospective controlled trials comparing DCBA versus POBA were searched through PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, ISI Web of Knowledge, and relevant websites without language or publication date restrictions. The keywords were "drug-eluting balloon," "angioplasty," "femoropopliteal," and "in-stent restenosis." We selected recurrent ISR, freedom from clinically driven target lesion revascularization (TLR), clinical improvement, ankle-brachial index (ABI), and major adverse events (MAEs) as the outcomes of this meta-analysis. Based on the inclusion criteria, we identified 3 prospective clinical trials. The one-year outcomes of DCBA and POBA were as follows: recurrent ISR (34.8% versus 73.1%, respectively; OR, 0.18; 95% CI, 0.10-0.32, Z = 5.56, P < 0.00001), freedom from clinically driven TLR (82.2% versus 54.1%, respectively; OR, 4.20; 95% CI, 2.05-8.61, Z = 3.92, P < 0.0001), clinical improvement (76.2% versus 55.7%, respectively; OR, 2.58; 95% CI, 1.41-4.72, Z = 3.07, P = 0.002), ABI (MD, -0.04; 95% CI, -0.13-0.04, Z = 1.01, P = 0.31), and MAEs (11.0% versus 18.3%, respectively; OR, 0.54; 95% CI, 0.25-1.15, Z = 1.60, P = 0.002).
Conclusions: For femoropopliteal ISR, DCBA is associated with superior efficacy outcomes compared with POBA, with the same safety outcome after a one-year follow-up. In the future, multicenter and large-scale prospective controlled trials comparing DCBA with other endovascular strategies are required to further assess the efficacy and safety profiles of DCBA in the treatment of femoropopliteal ISR.
Keywords: Drug-coated balloon; Femoropopliteal artery; In-stent restenosis.
Copyright © 2017. Published by Elsevier Ltd.
Similar articles
-
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries.Cochrane Database Syst Rev. 2019 Jan 26;1(1):CD012510. doi: 10.1002/14651858.CD012510.pub2. Cochrane Database Syst Rev. 2019. PMID: 30684445 Free PMC article.
-
Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial.Circulation. 2015 Dec 8;132(23):2230-6. doi: 10.1161/CIRCULATIONAHA.115.017364. Epub 2015 Oct 7. Circulation. 2015. PMID: 26446728 Clinical Trial.
-
Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.JACC Cardiovasc Interv. 2016 Jul 11;9(13):1386-92. doi: 10.1016/j.jcin.2016.04.012. JACC Cardiovasc Interv. 2016. PMID: 27388828 Clinical Trial.
-
Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.Circ Cardiovasc Interv. 2012 Aug 1;5(4):582-9. doi: 10.1161/CIRCINTERVENTIONS.112.969972. Epub 2012 Jul 31. Circ Cardiovasc Interv. 2012. PMID: 22851526
-
Paclitaxel-Coated versus Uncoated Balloon for Femoropopliteal In-Stent Restenosis: A Systematic Review and Meta-Analysis.Rev Cardiovasc Med. 2022 Sep 14;23(9):315. doi: 10.31083/j.rcm2309315. eCollection 2022 Sep. Rev Cardiovasc Med. 2022. PMID: 39077690 Free PMC article.
Cited by
-
Anti-atherosclerotic effects and molecular targets of salvianolic acids from Salvia miltiorrhiza Bunge.Front Pharmacol. 2025 May 21;16:1574086. doi: 10.3389/fphar.2025.1574086. eCollection 2025. Front Pharmacol. 2025. PMID: 40469984 Free PMC article. Review.
-
Research progress of metal biomaterials with potential applications as cardiovascular stents and their surface treatment methods to improve biocompatibility.Heliyon. 2024 Feb 7;10(4):e25515. doi: 10.1016/j.heliyon.2024.e25515. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38375258 Free PMC article. Review.
-
Drug-coated balloon in superficial femoral artery in-stent restenosis.Postepy Kardiol Interwencyjnej. 2018;14(1):9-14. doi: 10.5114/aic.2018.74350. Epub 2018 Mar 22. Postepy Kardiol Interwencyjnej. 2018. PMID: 29743899 Free PMC article. Review.
-
Efficacy and safety of drug-coated balloon versus non-drug-coated balloon combined with bare metal stent implantation in treatment of patients with occlusions of the superficial femoral artery: a retrospective study in clinical practice.Am J Transl Res. 2022 Feb 15;14(2):1305-1314. eCollection 2022. Am J Transl Res. 2022. PMID: 35273732 Free PMC article.
-
Twisting of the Ranger drug-coated balloon for treating superficial femoral artery disease.Clin Case Rep. 2022 Mar 1;10(3):e05505. doi: 10.1002/ccr3.5505. eCollection 2022 Mar. Clin Case Rep. 2022. PMID: 35251644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources